Register Now

Nomura lists four factors that will drive growth for Dr. Reddy’s beyond gRevlimid

The management of Dr. Reddy’s Laboratories expects to deliver double-digit growth, excluding gRevlimid in the base business. This excludes Semaglutide sales.

Leave a Reply

Your email address will not be published. Required fields are marked *